Please login to the form below

Eloctate

This page shows the latest Eloctate news and features for those working in and with pharma, biotech and healthcare.

Third time lucky? Sanofi cuts an $11.6bn deal to buy Bioverativ

Bioverativ separated from Biogen last year to create a stand-alone haemophilia specialist with two marketed drugs - Eloctate (efmoroctocog alfa) and Alprolix (eftrenonacog alfa) which brought in sales estimated to be ... longer acting therapies such as

Latest news

New data could unlock bigger market for Roche’s Hemlibra

Haemophilia A treatment is being transformed by a series of long-acting Factor VIII products such as Biogen’s Eloctate, Shire’s Adynovate, Bayer’s Kovaltry and CSLBehring’s Afstyla, which
Biogen spin-out makes first acquisition

Eloctate (efmoroctocog alfa) and Aprolix (eftrenonacog alfa).
Biogen completes haemophilia business separation

haemophilia A and B drugs, Eloctate (efmoroctocog alfa) and Aprolix (eftrenonacog alfa). ... The biotech was a latecomer to the $10bn haemophilia sector, but quickly gained ground with long-acting, low-dose therapies Eloctate and Aprolix, which
Sobi looks to real-world trial to push Elocta take-up

It took over EU commercialisation rights from partner Biogen – which sells the drug as Eloctate in the US - last March.
Biogen's CEO Scangos to step down

Long-acting Avonex follow-up Plegridy continued to gain ground - with sales up 65% to $123m - and there were also strong gains for Biogen's haemophilia drugs Eloctate and Alprolix, which

More from news
Approximately 3 fully matching, plus 19 partially matching documents found.

Latest Intelligence

Deal Watch January 2018

Paying $105 per share in cash (64% premium over Bioverativ’s closing price on 19 January), Sanofi gains the marketed products, Eloctate (haemophilia A therapy) and Alprolix (haemophilia B therapy), as ... During 2016 Eloctate and Alprolix generated

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Account Manager, Healthcare PR: £40, 000 – £42, 000 great benefits and bonuses

Account Manager – Med Comms – London: Salary TBC

Senior / Principal Regulatory Writer – Home Working - UK or US: HIGHLEY COMPETATIVE SALARY, BONUS &BENEFITS

Digital Senior Account Director – Healthcare Advertising – Londo...: Salary TBC

Senior Account Director, Healthcare Brand Communications, London: Excellent Package

Science writer, Healthcare Brand Communications, London, £45-50K...: £45-50K

Editorial Director – Medical Education – Oxford: Negotiable

Head of Operations/ BUD, Healthcare PR, London – Excellent leade...: Excellent Package

Editor – Medical Education Agency – Bucks: Salary TBC

Engagement Strategist, Healthcare Brand Communications, London, ...: Circa £60K

Editor > Senior Editor – Medical Education – London: Very competitive with excellent benefits

Senior Account Manager or AD - Medical Communications: Salary TBC

HOME BASED Senior Account Executive / Account Manager - Medical ...: Salary TBC

Group Account Director, Healthcare Brand Communications, London: Excellent Package

Editorial Team Leader or Scientific Director: £50, 000 - £55, 000 benefits

Medical Writer - (London, Brighton or Copenhagen): Competitive

Principal Medical Writer, Medical Communications, Relocate to Ca...: Excellent Salary

Scientific Director: Great salary and bebefits

Senior Account Manager – Med Comms – Kent: Salary TBC

Senior Account Manager / Account Director: Great salary and bebefits

FREELANCE OPPORTUNITIES!!!!! Medical Education - Healthcare Adve...: EXCELLENT DAY RATES AVAILABLE

FREELANCE Account Manager – Creative Healthcare Advertising – Lo...: SUPERB DAY RATES AVAILABLE

Medical Writer, e-learning/ training, London: Excellent Salary

Senior Medical Writer, Medical Communications, Relocate to Cardi...: Excellent Salary

Senior Medical Writer: Great salary and benefits

Subscribe to our email news alerts

PMHub

Add my company

Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement: Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance: Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies: Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...